#USA #Orange County #Medicare #MediPines #AGM100

Medicare Embraces Innovation with AGM100 Reimbursement

On August 6, 2025, MediPines, known for its pioneering non-invasive cardiorespiratory technology, announced a major development in the healthcare reimbursement landscape. The AGM100®, a device that assesses cardiorespiratory conditions rapidly and non-invasively, has received approval for facility reimbursement under the Medicare framework through the Ambulatory Payment Classification (APC) system. This significant milestone allows hospitals, ambulatory surgical centers (ASCs), and outpatient facilities to receive proper reimbursement for the critical assessments performed using AGM100.

A Regulatory Milestone: CPT and APC Approval

The introduction of CPT code 0893T marks a transformative moment in healthcare. This code facilitates the non-invasive evaluation of vital parameters such as blood oxygenation and gas exchange efficiency. Securing APC mapping alongside this CPT code is a testament to Medicare’s support of innovative medical technology that demonstrates both clinical utility and economic value. MediPines is actively working with the Centers for Medicare & Medicaid Services (CMS), Medicare Administrative Contractors (MACs), and private insurers to optimize reimbursement structures that acknowledge the growing applications and value of the AGM100 in clinical practice.

Broader Clinical Applications

The AGM100’s newly established CPT code encompasses a comprehensive range of clinical scenarios, especially those associated with severe cardiopulmonary conditions such as heart failure, Chronic Obstructive Pulmonary Disease (COPD), pulmonary embolism, pulmonary hypertension, interstitial lung disease syndrome (ILDS), and acute respiratory distress syndrome (ARDS). This extensive applicability confirms the AGM100's relevance not only in acute care settings but also in effective patient management strategies.

High-Precision Diagnostic Capabilities

Research backs the AGM100’s capabilities, showcasing a predictive accuracy with an area under the curve (AUC) of 0.98, indicating very high reliability in detecting respiratory impairments in acute care settings. Independent studies published in reputable journals, such as the Journal of Clinical Medicine, confirm these findings. The device has demonstrated the ability to anticipate clinical deterioration and the necessity for immediate healthcare interventions, which is vital for patient outcomes.

The AGM100's capacity to provide precise Oxygen Deficit measurements adds substantial value to existing imaging modalities like V/Q scans and CT pulmonary angiography (CTPA), serving as a supportive diagnostic tool that enhances clinical decision-making.

Expert Endorsements

“The operational status for APC placement is an important step forward for the field of cardiorespiratory medicine,” stated Steve Lee, CEO of MediPines. He emphasized the AGM100's role in addressing gaps left by traditional imaging techniques, noting that the device's ability to supply rapid and actionable data at points of care empowers clinicians to make prompt and informed decisions.

Dr. Aidan Raney, a former Medical Director of Cardiovascular Surgery, also endorsed the AGM100, recommending its integration as standard practice in various healthcare settings for enhanced cardiorespiratory evaluation. He highlighted its non-invasive nature, speed of operation, and reliable results as key advantages.

With a comprehensive assessment capability generated in just two minutes, the AGM100 significantly improves decision-making processes in emergency and outpatient environments, which is crucial for optimizing patient outcomes.

About MediPines

MediPines stands at the forefront of non-invasive pulmonary gas exchange technology, with the AGM technology co-developed alongside renowned respiratory physiologist Dr. John B. West. The AGM100 has gained recognition from the World Health Organization as an innovative health product suitable for rapid point-of-care assessments. For additional implementation support or inquiries, contact [email protected].

For media inquiries, contact Andrew McFadden at 949.398.4670 or via email at email protected]. Visit [www.medipines.com for more information.